Mitochondrial apoptosis and BH3 mimetics
The BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances i...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
F1000Research
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133681/ |